SJ-600 Series / SillaJen - LARVOL DELTA

Shillajen-Reithera Sign CDMO Agreement for Oncological Virus Platform [Google translation] (HIT News) - "ShillaJen...announced on the 21st that it has signed a comprehensive collaboration agreement (MSA) with Italian global CDMO (Contract Development and Manufacturing Organization) company ReiThera for the contract development and manufacturing of the 'SJ-600' series of anticancer virus platforms...Through this agreement, Reithera will develop Shillajen's SJ-600 series as a GMP drug for clinical trials and support its mass production....ShillaJen said that it expects to be able to efficiently proceed with the process development and GMP production of the SJ-600 series based on Reithera’s experience and infrastructure."

Licensing / partnership • Oncology • Solid Tumor

‘Pexa-Vec’ SillaJen, return of bio representative player?... Successful bequest of 100 billion won [Google translation] (Investing.com) - "Shinlazen, which narrowly escaped the crisis after going to the brink of delisting, is showing signs of recovery. It has also succeeded in securing R&D funds by raising paid-in capital of 100 billion won....Sillazen plans to invest nearly 90 billion won of the funds secured this time into R&D for PEXA-VEC, BAL0891, SJ-600 series. The remaining funds are expected to flow into the U.S. subsidiary Sillazen Bio. The plan is to get back on track by focusing resources on anti-cancer R&D, including kidney cancer and solid cancer."

Financing • Kidney Cancer • Oncology • Solid Tumor

SillaJen meets with partner Regeneron at Bio USA [Google translation] (HIT News) - "SillaJen...announced on the 11th that it discussed various cooperation plans with global pharmaceutical companies from each country at the 'Bio International Convention 2024 (hereinafter referred to as Bio USA)' held in San Diego, USA from the 3rd to the 6th...According to the company, this year's event schedule included various discussions on each pipeline (new drug candidate) that was more advanced than before. In the case of Pexa-Vec, which completed phase 2a kidney cancer treatment, a business meeting was held with partner Regeneron. Senior officials from both companies attended and discussed licensing out (L/O) and development expansion....Sillajen announced that in addition to Pexa-Vec, it also held meetings about BAL0891 and SJ-600 series, which Sillajen is developing." "

Clinical • Licensing / partnership • Breast Cancer • Colorectal Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor